Peanut allergy patch: a new hope for kids?
NCT ID NCT01197053
First seen Aug 21, 2026 · Last updated Aug 21, 2026
Summary
This trial tests whether a skin patch delivering peanut proteins can safely desensitize children with peanut allergy. Children aged 5 to 17 will wear the patch daily for six months, and researchers will check if they can eat more peanut without symptoms. The goal is to see if this approach can reduce the risk of severe reactions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Epicutaneous immunotherapy with peanut proteins applied as a skin patch
- What this could lead to
- If successful, this could offer a practical, needle-free way to reduce peanut allergy reactions in children, potentially lowering the risk of severe reactions from accidental exposure.
- What could go wrong
- This is an early-phase pilot study with a small number of participants. The patch may not work for everyone, and there is a risk of skin irritation or allergic reactions at the application site.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
60 people
The number who actually took part.
- Start date
-
Aug 2010
- Finished
-
Apr 2015
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
5 to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or Female between 5 and 17 years of age at enrollment * An efficient contraceptive method for girls with childbearing potential. Acceptable methods include sexual abstinence, oral, injectable contraceptive methods, intra uterine device. * Negative pregnancy test for girls with childbearing potential. * Child with a documented allergy to peanut, i.e. with peanut-specific IgE (\>5KU/L, ImmunoCAP method) and/or a positive skin prick test to peanut (wheal diameter ≥ 8mm). * Child able to consume a cumulated quantity of peanut proteins \<250 mg during the baseline DBPCFC. * Child and his/her legal representative(s) who provide a signed consent form and assent form. * Child and his/her legal representative(s) whose family and social conditions allow them to understand the protocol and agree to comply in the long term with all study requirements. Exclusion criteria : * Child considered too severely allergic to peanut: with a history of severe anaphylaxis to peanut (with hypotension, loss of consciousness, severe bradycardia, respiratory or cardiac arrest requiring an admission to emergency rooms). * Child with peanut-specific IgE\<5 KU/L and whose skin prick test to peanut gave a wheal diameter \<8mm). * Child participating or having participated in a therapeutic study in the last 3 months * Pregnancy or Breastfeeding * Child with a generalized eczema * Child with an immune deficiency * Diabetic child * Child allergic to chocolate * Child or legal representative(s) who did not sign their consent or assent * Child with no baseline DBPCFC * Child having reacted to placebo during the baseline DBPCFC * Child able to consume \> 250 mg of cumulated peanut proteins during the baseline DBPCFC * Child with a respiratory deficiency or with an uncontrolled asthma. * Child who could not discontinue oral or I.V. antihistamines or oral or I.V. corticosteroids at least the week prior to Visit 1. * Child with important skin lesions precluding the application of the disks. * Child not affiliated to social security.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Peanut allergy are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopital Necker
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A pill that could outsmart food allergies? trial tests remibrutinib
- Peanut allergy cure in sight? trial tests tolerance in teens
- Can a shot tame peanut allergies? small study tests xolair
- Can allergy drugs help kids tolerate peanut and more?
- Peanut allergy patch enters human safety trials
- Could supermarket peanuts and milk cure food allergies? new study investigates.